Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

1478108

USP

Ofloxacin

United States Pharmacopeia (USP) Reference Standard

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C18H20FN3O4
Numero CAS:
82419-36-1
Peso molecolare:
361.37
Numero MDL:
MFCD00226105
Codice UNSPSC:
41116107
ID PubChem:
329750600
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

ofloxacin, ofloxacin

Produttore/marchio commerciale

USP

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

CC1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O

InChI

1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
GSDSWSVVBLHKDQ-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Ofloxacin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Ofloxacin Tablets
  • Ofloxacin Ophthalmic Solution
  • Levofloxacin

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

Levofloxacin Related Compound B United States Pharmacopeia (USP) Reference Standard

USP

1362125

Levofloxacin Related Compound B

Tinidazole United States Pharmacopeia (USP) Reference Standard

USP

1667520

Tinidazole

Gatifloxacin United States Pharmacopeia (USP) Reference Standard

USP

1288408

Gatifloxacin

Fluconazole United States Pharmacopeia (USP) Reference Standard

USP

1271700

Fluconazole

Levofloxacin 98.0-102.0% anhydrous basis (HPLC)

Sigma-Aldrich

28266

Levofloxacin

Dispositivo Steritest® NEO For liquids in ampoules or collapsible bags. Blue base canister with a single-needle adapter. Single packed.

Millipore

TZHALA210

Dispositivo Steritest® NEO

Levofloxacin Hemihydrate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1697

Levofloxacin Hemihydrate

Cloramfenicolo ≥98% (HPLC)

Sigma-Aldrich

C0378

Cloramfenicolo

Gentamicina meets USP testing specifications, powder

Sigma-Aldrich

G1914

Gentamicina

J P Monk et al.
Drugs, 33(4), 346-391 (1987-04-01)
Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Ciprofloxacin is the only other
Mahesh D Chavanpatil et al.
International journal of pharmaceutics, 316(1-2), 86-92 (2006-03-29)
Oral sustained release gastroretentive dosage forms offer many advantages for drugs having absorption from upper gastrointestinal tract and improve the bioavailability of medications that are characterized by a narrow absorption window. A new gastroretentive sustained release delivery system was developed
Shu-Hwa Hsiao et al.
The Annals of pharmacotherapy, 39(1), 146-149 (2004-11-25)
To report a case of ofloxacin/levofloxacin-induced rhabdomyolysis and to compare other reported cases from the literature. A 19-year-old male patient developed ofloxacin/levofloxacin-induced rhabdomyolysis during admission for periorbital cellulitis. Symptoms of myalgia, weakness, and swelling of the arms developed after 3
S M Traeger et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 21(6), 1504-1506 (1995-12-01)
We describe four patients who had seizures while receiving ofloxacin; no other causes were evident. Common factors among all patients included advanced age and use of a high-dose regimen. The renal insufficiency of three patients and the timing of the
G A Gates
The Pediatric infectious disease journal, 20(1), 104-107 (2001-02-15)
To assess the safety of topical agents in the middle ear, animal studies were reviewed. Compared with aminoglycoside-containing preparations, which caused significant loss of hair cells in the basal turn of the cochlea, ofloxacin caused no loss of hair cells
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.